EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treosulfan A classical alkylating agent new in high-dose combination chemotherapy



Treosulfan A classical alkylating agent new in high-dose combination chemotherapy



Onkologie 23(Sonderheft 7): 128, October




(PDF 0-2 workdays service: $29.90)

Accession: 035985730

Download citation: RISBibTeXText



Related references

High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. Journal of Clinical Oncology 4(11): 1592-1597, 1986

Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. Archives of Dermatology 124(6): 878-884, 1988

Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. Journal of Clinical Oncology 13(5): 1136-1143, 1995

Dose-escalation of treosulfan in combination with carboplatin and etoposide as high-dose chemotherapy of advanced ovarian carcinoma. Annals of Hematology 77(SUPPL 2): S118, 1998

High dose combination alkylating agent therapy with autologous bone marrow support abms as initial chemotherapy for metastatic breast cancer mbc. Proceedings of the American Association for Cancer Research Annual Meeting 28: 227, 1987

Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy. European Journal of Cancer 27(5): 561-565, 1991

Prevention of hemorrhagic cystitis after high-dose alkylating agent chemotherapy and autologous bone marrow support. Bone Marrow Transplantation 14(2): 287-291, 1994

High-dose combination alkylating agent therapy with autologous bone marrow rescue for refractory solid tumors. Journal of Clinical Oncology 6(8): 1314-1320, 1988

High dose combination alkylating agent therapy and autologous bone marrow support for solid tumors an update. International Journal of Cell Cloning 3(4): 257-258, 1985

High dose combination alkylating therapy with bone marrow support bms as initial chemotherapy for metastatic breast cancer mbc. Breast Cancer Research & Treatment 10(1): 89, 1987

High dose alkylating agent chemotherapy with autologous bone marrow abm support in patients pts with stage iii iv epithelial ovarian cancer oca. Journal of Cellular Biochemistry Supplement (14 PART A): 323, 1990

High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecologic Oncology 38(3): 386-391, 1990

High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. Cancer 63(7): 1296-1302, 1989

High dose combination alkylating agents with autologous bone marrow support as initial chemotherapy for metastatic breast cancer. Uicc (Union Internationale Contre Le Cancer, International Union Against Cancer) 14th International Cancer Congress, Budapest, Hungary, Aug 21-27, Abstracts, Lectures, Symposia And Free Communications, Vols 1, 2, 3, Late Abstracts, And Register Xvi+479p (Vol 1); Xvi+298p (Vol 2); Xvi+531p (Vol 3); 15p (Late Abstracts); 40p (Register) S Karger Ag: Basel, Switzerland; New York, N Y , Usa; Akademiai Kiado: Budapest, Hungary Paper 737, 1986

High dose combination alkylating agent therapy with autologous bone marrow support as initial treatment for metastatic breast cancer. Breast Cancer Research & Treatment 8(1): 80, 1986